Kaken Pharmaceutical Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Kaken Pharmaceutical has a total shareholder equity of ¥142.5B and total debt of ¥3.9B, which brings its debt-to-equity ratio to 2.7%. Its total assets and total liabilities are ¥174.8B and ¥32.3B respectively. Kaken Pharmaceutical's EBIT is ¥9.0B making its interest coverage ratio -17.9. It has cash and short-term investments of ¥66.6B.
Belangrijke informatie
2.7%
Verhouding schuld/eigen vermogen
JP¥3.85b
Schuld
| Rente dekkingsratio | -17.9x |
| Contant | JP¥66.56b |
| Aandelen | JP¥142.52b |
| Totaal verplichtingen | JP¥32.26b |
| Totaal activa | JP¥174.78b |
Recente financiële gezondheidsupdates
Geen updates
Analyse van de financiële positie
Kortlopende schulden: 4521's short term assets (¥109.1B) exceed its short term liabilities (¥23.1B).
Langlopende schulden: 4521's short term assets (¥109.1B) exceed its long term liabilities (¥9.2B).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 4521 has more cash than its total debt.
Schuld verminderen: 4521's debt to equity ratio has reduced from 3.2% to 2.7% over the past 5 years.
Schuldendekking: 4521's debt is well covered by operating cash flow (66.9%).
Rentedekking: 4521 earns more interest than it pays, so coverage of interest payments is not a concern.